Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IDVY | 27.04 | 0.49 | +1.84% |
| First Trust International Ris Div AchETF | |||
| DIVI | 44.12 | 0.43 | +0.98% |
| Franklin Intl Core Div Tlt Idx ETF | |||
| BBH | 229.39 | 0.76 | +0.33% |
| VanEck Biotech ETF | |||
| SIFI | 42.71 | N/A | N/A |
| Harbor Ares Systematic Mltsct Inc ETF | |||
| FTRI | 18.24 | -0.02 | -0.08% |
| First Trust Indxx Glbl Natrl Res Inc ETF | |||
A.I.dvisor indicates that over the last year, GPCR has been loosely correlated with WVE. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GPCR jumps, then WVE could also see price increases.
| Ticker / NAME | Correlation To GPCR | 1D Price Change % | ||
|---|---|---|---|---|
| GPCR | 100% | -2.25% | ||
| WVE - GPCR | 64% Loosely correlated | -1.71% | ||
| KYMR - GPCR | 62% Loosely correlated | -1.74% | ||
| NRIX - GPCR | 45% Loosely correlated | -2.75% | ||
| OCUL - GPCR | 42% Loosely correlated | -1.22% | ||
| FULC - GPCR | 40% Loosely correlated | N/A | ||
More | ||||
GPCR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 20, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In 33 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GPCR as a result. In 45 of 58 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
GPCR moved below its 50-day moving average on August 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GPCR crossed bearishly below the 50-day moving average on August 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where GPCR advanced for three days, in 173 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 81 of 103 cases where GPCR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.033) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (27.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.527). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (427.627).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.